Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

American Journal of Pathology

Volumn 154, Issue 6, 1999, Pages 1743-1753

  Seo, Man Seong ^a,c   Kwak, Nohoon ^a   Ozaki, Hiroaki ^a,d   Yamada, Haruhiko ^a   Okamoto, Naoyuki ^a   Yamada, Eri ^a   Fabbro, Doriano ^b   Hofmann, Francesco ^b   Wood, Jeanette M ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Chonnam National University Medical School   (South Korea)

^d FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MIDOSTAURIN; PROTEIN KINASE C INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRUCH MEMBRANE; CONTROLLED STUDY; DRUG ACTIVITY; MEMBRANE DAMAGE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION;

EID: 0000379427     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65430-2     Document Type: Article

References (38)

1. Pournaras CJ, Tsacopoulos M, Strommer K, Gilodi N, Leuenberger PM: Scatter photocoagulation restores tissue hypoxia in experimental vasoproliferative microangiopathy in miniature pigs. Ophthalmology 1990, 97:1329-1333
2. The Diabetic Retinopathy Research Study Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88:583-600
3. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy: five year results from randomized clinical trials. Arch Ophthalmol 1991, 109:1109-1114
4. Forsythe JA, Jiang B-H, Iyer NV, Agani F. Leung SW, Koos RD, Semenza G: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16: 4604-4613
5. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270:13333-13340
6. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995, 15:4738-4747
7. Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, Yeo T-K, Yeo K-T: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen MS, Aiello LM, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487
9. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994, 112:1476-1482
10. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E: Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995, 72:638-645
11. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, Yeo T-K, Yeo K-T: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model, Am J Pathol 1994, 145:574-584
12. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995, 92:905-909
13. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997, 151:281-291
14. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995, 92:10457-10461
15. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LES: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996, 93:4851-4856
16. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophthalmol 1996, 114:66-71
17. Smith LEH, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276: 1706-1709
18. Inoguchi T, Battan R, Handler R, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992, 89:11059-11063
19. Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480
20. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY 333531. Invest Ophthalmol Vis Sci 1998, 39:171-179
21. Brooks P, Clark R, Cheresh D: Requirement of vascular integrin α-v β-3 for angiogenesis. Science 1994, 264:569-571
22. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA: Antagonists of integrin α-v β-3 inhibit retinal neovascularization in a murine model. Lab invest 1996, 75:563-573
23. Hammes H, Brownlee M, Jonczyk A, Sutter A, Preissner K: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996, 2:529-533
24. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988, 334:661-665
25. Tamaoki T, Hisayo N, Takahashi I, Kato Y, Morimoto M, Tomita F: Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun 1986, 135:397-402
26. Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G, Matter A: A derivative of staurosporin (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 1989, 43:851-856
27. Miggli V, Keller H: On the role of protein kinases in regulating neutrophil actin association with the cytoskeleton J Biol Chem 1991, 266:7927-7932
28. Chung DL, Brandt-Rauf PW, Weinstein IB, Nishimura S, Yamaizumi Z, Murphy RB, Pincus MR: Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C. Proc Natl Acad Sci USA 1992, 89:1993-1996
29. Marte BM, Meyer T, Stabel S, Standke GJR, Jaken S, Fabbro D, Hynes NE: Protein kinase C and mammary cell differentiation: involvement of protein kinase C α in the induction of β-casein expression. Cell Growth Differ 1994, 5:239-247
30. Oh LYS, Goodyer CG, Olivier A, Yong VW: The promoting effects of bFGF and astrocyte extracellular matrix on process outgrowth by adult human oligodendrocytes are mediated by protein kinase C. Brain Res 1997, 757:236-244
31. Meggio F, Donella-Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, Dobrowolska G, Pinna LA: Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 1995, 234:317-322
32. Smith LEH, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA: Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35:101-111
33. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, Campochiaro PA: Evolution of neovascularization in mice with over-expression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998, 39:180-188
34. Tobe T, Ortega S, Luna L, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA: Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998, 153:1641-1646
35. Blanks JC, Johnson LV: Vascular atrophy associated with photoreceptor degeneration in mutant mice. Retinal Degeneration: Experimental and Clinical Studies. Edited by LaVail MM, Hollyfield JG, Anderson RE. New York, Alan R Liss, 1985, pp 189-207
36. Klein R, Klein B: Vision disorders in diabetes. Diabetes in America, ed 2. Edited by National Diabetes Data Group, Washington, DC, National Institutes of Health, 1995, p 294
37. Alon T, Hemo I, Itin A, Pe'er J, Stone J. Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1995, 1:1024-1028
38. Ryan SJ: Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol 1982, 100:1804-1809